Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sarepta Therapeutics Inc : SRPT, FB, CRUS and OMER added to NASDAQ Active Stock Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/24/2013 | 03:05pm CEST

New York, NY - (ACCESSWIRE) - 09/24/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Facebook, Inc. (NASDAQ:FB), Cirrus Logic Inc. (NASDAQ:CRUS), and Omeros Corporation (NASDAQ:OMER)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) a biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases closed up in its previous session (+10.79%) on 6,581,320 shares traded after Sarepta was upgraded to Overweight from Neutral at Piper Jaffray. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is currently up (+251.61%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=SRPT&SubId=AW

Facebook, Inc. (NASDAQ:FB) operates as a social networking company worldwide closed down in its previous session (-0.63%) on 75,274,915 shares traded after Facebook Quietly Rolls Out Its Mobile Payments Autofill Product, AllThingsD Reported. Facebook, Inc. (NASDAQ:FB) is currently down (-2.75%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Facebook, Inc. (NASDAQ:FB)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=FB&SubId=AW

Cirrus Logic Inc. (NASDAQ:CRUS) a fabless semiconductor company that develops analog and mixed-signal integrated circuits for a range of consumer and industrial markets closed up in its previous session (+5.41%) on 6,219,309 shares traded after CIRRUS LOGIC INC Filed SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year. Cirrus Logic Inc. (NASDAQ:CRUS) is currently up (+46.96%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Cirrus Logic Inc. (NASDAQ:CRUS)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CRUS&SubId=AW

Omeros Corporation (NASDAQ:OMER) a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system closed up in its previous session (+28.21%) on 8,095,031 shares traded after Omeros has been Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference on Friday, September 27, 2013. Omeros Corporation (NASDAQ:OMER) is currently up (+167.95%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Omeros Corporation (NASDAQ:OMER)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=OMER&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAREPTA THERAPEUTICS INC
05/04 SAREPTA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
05/01 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
04/27 SAREPTA THERAPEUTICS : tops Street 1Q forecasts
04/27 SAREPTA THERAPEUTICS, INC. (NASDAQ : SRPT) Files An 8-K Departure of Directors o..
04/27 SAREPTA THERAPEUTICS, INC. (NASDAQ : SRPT) Files An 8-K Results of Operations an..
04/27 Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recen..
04/27 SAREPTA THERAPEUTICS : Scott+Scott, Attorneys at Law, LLP Reminds Investors of i..
04/27 SAREPTA THERAPEUTICS INC : Investor Network: Sarepta Therapeutics, Inc. to Host ..
04/27 SAREPTA THERAPEUTICS : Metropolitan Life Insurance Co. NY Acquires 3,717 Shares ..
04/21 SAREPTA THERAPEUTICS : to Announce First Quarter 2017 Financial Results and Rece..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/19 I'm Surprised That They're Surprised
05/18 Sarepta hired former FDA lawyer to help guide parents' testimony during etepl..
05/18 Sarepta perks up 3% after Tourbillon's Karp says he's long the stock
05/12 'Benign' briefing papers send Sarepta up more than 3%
05/04 Biotech Bonanza - Approaching An Inflection Point
Advertisement
Financials ($)
Sales 2017 108 M
EBIT 2017 -132 M
Net income 2017 -64,0 M
Finance 2017 232 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 14,4x
EV / Sales 2018 6,90x
Capitalization 1 785 M
More Financials
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | SRPT | US8036071004 | 4-Traders
Full-screen chart
Technical analysis trends SAREPTA THERAPEUT...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 60,9 $
Spread / Average Target 88%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edward M. Kaye President & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Catherine Stehman Breen Chief Medical Officer
Hans Lennart Rudolf Wigzell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS I..12.47%1 796
AMGEN, INC.6.31%112 531
CELGENE CORPORATION0.86%90 349
GILEAD SCIENCES, INC.-9.85%84 101
REGENERON PHARMACEUTIC..24.83%48 999
ACTELION LTD26.30%30 824
More Results